| |
 |
This is the category page. Below are all of the research programs that are associated with it
- Blood Clots -
ADOPT: APIXABAN DOSING TO OPTIMIZE PROTECTION FROM THROMBOSIS , A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF APIXABAN FOR PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL SUBJECTS DURING AND FOLLOWING HOSPITALIZATION (PROTOCOL: CV185036)
(1_20080802_118)
This study will compare two drugs, Apixaban which is investigational; and Enoxaparin, which is FDA approved. The participant will be randomized to either of the two drugs. The treatment period will last for 30 days; treatment visits will include visit 1-day one; visit-2, day of discharge; and then day 14 and day 30. Participants will be evaluated for symptomatic bleeding events/clots. Participants will have mandatory bilateral compression ultrasound between day 5 and day 14 and then again on day 30. Follow-up period extends to day 60 and day 90. Blood samples will be taken at each study visit during the treatment period.
- Cholesterol -
NON-FASTING POINT OF CARE (POC) ASSESSMENT OF CHOLESTEROL LEVELS: ACCURACY, COST, IMPACT ON CLINICAL DECISION MAKING AND PATIENT SATISFACTION. (Investigator Initiated Protocol)
(2_20070915_118)
A total of 210 patients will be studied. The first 70 patients randomized will receive both a fasting blood draw and a non-fasting finger-stick cholesterol test. The next 140 patients enrolled will be randomized to one of two groups, each group with 70 patients. Patients in Group 1 will only be tested with fasting blood-draw cholesterol, patients in Group 2 will only be tested with non-fasting finger-stick cholesterol. A patient satisfaction survey and a patient enablement assessment will be administered to all study participants, one week after the lipid panel is obtained. A four month follow-up fasting blood-draw lipid panel will be obtained to determine if NCEP cholesterol treatment goals are achieved.
|
|
